Efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in patients with chronic kidney disease: meta-analysis of phase 3 randomized controlled trials.

"CONFLICT OF INTEREST STATEMENT R.M. has been a member of Advisory Boards for Amgen, Astellas and GSK, consulted for Bayer and GSK, and has been an invited speaker at meetings supported by Amgen, Astellas, Vifor Pharma and AstraZeneca. M.E.L.: none. V.S.: none. F.C.S. has been a member of Advisory Boards for Boehringer and Ely-Lilly, and has received fees for scientific consultation and/or lectures by Jansen, Roche Diagnostics, Novo Nordisk, Sanofi, MSD and AstraZeneca. S.B.: none. L.D.N. has received fees for scientific consultation and/or lectures by Amgen, Astellas, AstraZeneca, GSK, Mundibiopharma and Vifor Pharma. C.G.: none."

"FUNDING This research did not receive any grant, funds, fees and support."

"The present review was conducted in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines []. We searched relevant articles published from inception until 31 December 2022 by using PubMed, SCOPUS and ISI Web of Science databases. The search strategy is reported in . References of articles and reviews found in research were further screened to identify additional studies. The present systematic review and meta-analysis was registered in Prospero CRD42023397997."